Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health STI Diagnostic Coverage Update | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentOscar HealthPolicy N/A

    Diagnostic Testing of Common Sexually Transmitted Infections

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage and limitations for laboratory testing of common STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum, Trichomonas vaginalis, HSV, HPV, and Mycoplasma genitalium) for Oscar Health members. Applies to providers submitting claims to Oscar and outlines when specific tests meet criteria or do not meet criteria.

    Policy Summary
    PayerOscar Health
    PolicyDiagnostic Testing of Common Sexually Transmitted Infections
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionUse two-tiered serologic testing (treponemal plus nontreponemal) for syphilis diagnosis and document test type and clinical indications when submitting claims.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6primary pathogens covered
    23coverage statements listed
    1.5Mreported chlamydia cases (US, 2024)
    543Kreported gonorrhea cases (US, 2024)
    42%syphilis rate increase (2019–2024)

    Coverage Criteria for STI Diagnostic Testing

    Syphilis antibody testing (meets criteria)

    Covered when any of the following FOR SYPHILIS antibody testing are met

    Syphilis antibody testing - high-risk asymptomatic: For any asymptomatic person in a high-risk category, once a year assessment using either a standard or reverse algorithm that includes initial and confirmatory tests for any initial positive test (e.g., treponemal and nontreponemal tests)annual

    See Notes 1 & 2 for high-risk definitions

    Syphilis antibody testing - symptomatic: Diagnosis for any person presenting with signs and/or symptoms of syphilisone-time as indicated

    See Note 3 for signs/symptoms

    Syphilis - HIV-positive/MSM frequent screening:
    Policy Summary
    PayerOscar Health
    PolicyDiagnostic Testing of Common Sexually Transmitted Infections
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionUse two-tiered serologic testing (treponemal plus nontreponemal) for syphilis diagnosis and document test type and clinical indications when submitting claims.
    SourceLink
    On This Page
    Coverage Criteria for STI Diagnostic TestingProcedure and Proprietary Test CodesProvider Responsibilities, Prior Authorization & DocumentationClinical Background and RationaleDefinitions and Key TermsPolicy Revision History
    Once every three months for HIV-positive men or men who have sex with men (MSM)
    q3 months
    Syphilis - pre-transplant: Treponemal and nontreponemal testing once prior to allogeneic hematopoietic stem cell transplant in donors and recipientspre-transplant
    Syphilis - test of cure: Nontreponemal test when used as test of cure for a positive syphilis infectionas clinically indicated

    Syphilis - Not medically necessary / Not covered

    Not covered situations for syphilis testing

    Treponemal testing in previously or currently infected: For individuals currently diagnosed with syphilis or with a past history of syphilis infection, treponemal Ig testing does NOT meet criteria
    Syphilis PCR/NAAT/antigen: Polymerase chain reaction (PCR), nucleic acid amplification testing (NAAT), and antigen testing for syphilis DO NOT MEET CRITERIA

    NAAT/PCR for Treponema pallidum is not FDA-approved and not typically performed for genital syphilis

    Chlamydia NAAT (meets criteria)

    Covered when any of the following FOR CHLAMYDIA NAAT are met

    Chlamydia NAAT - high-risk asymptomatic: Once a year assessment for any asymptomatic person in a high-risk categoryannual

    See Notes 1 & 4

    Chlamydia NAAT - symptomatic: Diagnosis for any person presenting with signs and/or symptoms of chlamydial infectionas indicated

    See Note 5

    Chlamydia NAAT - LGV: Diagnosis for suspected lymphogranuloma venereum (LGV)as indicated

    Request genotyping for LGV when C. trachomatis is detected

    Chlamydia NAAT - test of cure non-pregnant: At least three months after initial diagnosis as test of cure for non-pregnant individuals>=3 months
    Chlamydia NAAT - test of cure pregnant: At least four weeks after initial diagnosis as test of cure for pregnant individuals>=4 weeks

    Chlamydia NAAT - Limited screening

    Chlamydia screening in low-risk asymptomatic individuals

    Chlamydia NAAT - limited low-risk screening: For asymptomatic individuals NOT in high-risk groups, NAAT screening meets criteria only for pregnant individuals 24 years or younger at first prenatal visit, newborn screening, victims of sexual assault follow-up, and sexually active individuals <18 years annuallyage- and situation-specific

    See Note 4

    Chlamydia - Not medically necessary / Not covered

    Chlamydia - Not covered

    Chlamydia culture/antibody/antigen: Culture testing, antibody testing, and antigen testing for chlamydia or LGV DO NOT MEET CRITERIA

    Gonorrhea NAAT (meets criteria)

    Covered when any of the following FOR GONORRHEA NAAT are met

    Gonorrhea NAAT - high-risk asymptomatic: Once a year assessment for any asymptomatic person in a high-risk categoryannual

    See Notes 1 & 4

    Gonorrhea NAAT - symptomatic: Diagnosis for any person presenting with signs and/or symptoms of gonorrheal infectionas indicated

    See Note 6

    Gonorrhea - test of cure: At least three months after initial gonorrhea diagnosis as test of cure>=3 months

    Gonorrhea - antimicrobial susceptibility via culture

    Gonorrhea - Additional covered testing

    Gonorrhea culture for resistance: For individuals that do not respond to initial treatment, culture testing for N. gonorrhoeae to determine antimicrobial susceptibility MEETS CRITERIAas clinically indicated

    Maintain culture capacity for suspected treatment failure and surveillance

    Gonorrhea NAAT - Limited screening

    Gonorrhea screening in low-risk asymptomatic individuals

    Gonorrhea NAAT - limited low-risk screening: For asymptomatic individuals NOT in high-risk groups, NAAT screening meets criteria only for pregnant individuals 24 years or younger at first prenatal visit, newborn screening, victims of sexual assault follow-up, and sexually active individuals <18 years annuallyage- and situation-specific

    Trichomonas vaginalis NAAT (meets criteria)

    Trichomonas vaginalis testing

    T. vaginalis NAAT - symptomatic: Qualitative NAAT for T. vaginalis MEETS CRITERIA for symptomatic individualsas indicated

    See Note 7

    T. vaginalis NAAT - follow-up: Follow-up testing a minimum of three months after initial trichomoniasis diagnosis>=3 months

    Retest ~3 months due to reinfection risk

    T. vaginalis NAAT - annual high-risk: Annual screening for asymptomatic individuals in a high-risk group or who have HIVannual

    See Note 8

    Trichomonas - Not medically necessary / Not covered

    Trichomonas - Not covered

    T. vaginalis rapid EIA: Rapid identification of Trichomonas by enzyme immunoassay DOES NOT MEET CRITERIA

    Wet mount has low sensitivity; use NAAT where possible

    Mycoplasma genitalium testing

    Mycoplasma genitalium testing

    M. genitalium NAAT - symptomatic: For symptomatic individuals, testing for M. genitalium using qualitative NAAT MEETS CRITERIAsymptomatic only

    See Note 9 for symptom details (e.g., urethritis, cervicitis)

    M. genitalium NAAT - asymptomatic: For asymptomatic individuals, screening for M. genitalium using NAAT DOES NOT MEET CRITERIA

    CDC does not recommend asymptomatic screening

    Multitarget PCR (meets criteria)

    Multitarget PCR testing coverage

    Multitarget PCR - limited targets: When an individual meets conditions above, multitarget PCR testing (targets limited to C. trachomatis, N. gonorrhoeae, T. vaginalis, and M. genitalium) MEETS CRITERIA

    Multiplex assays acceptable when limited to listed targets

    Herpes simplex virus testing

    Herpes simplex virus testing

    HSV NAAT - lesions: For individuals with active genital ulcers or mucocutaneous lesions, qualitative NAAT for HSV-1 or HSV-2 MEETS CRITERIAlesion-present

    PCR/NAAT preferred for lesion testing

    HSV type-specific serology: Type-specific antibody testing for HSV-2 using a glycoprotein G2 (gG2) test MEETS CRITERIA for recurrent or atypical symptoms with negative PCR/culture, for clinical diagnosis when PCR/culture negative or without lab confirmation, or when partner has genital herpesspecific clinical scenarios

    CDC-recommended contexts

    HSV antibody/antigen tests not covered: Antibody and antigen testing for HSV-1 and/or HSV (non-specific type test) and antigen testing for HSV-2 DO NOT MEET CRITERIA

    Routine serologic screening of asymptomatic individuals not recommended

    HSV screening asymptomatic: In asymptomatic individuals, screening for HSV-1 or HSV-2 DOES NOT MEET CRITERIA

    USPSTF recommends against routine serologic screening

    HPV testing

    HPV testing

    HPV for cancer diagnosis/assessment: In the diagnosis and/or assessment of cancer or cancer therapy (IHC for p16 or NAAT for high-risk HPV), testing for high-risk HPV MEETS CRITERIAcancer-related

    Use per oncologic or cytology indications

    HPV - not covered in general STI panels: Testing for HPV does NOT MEET CRITERIA to screen for oncogenic high-risk types as part of a general STI screening panel for asymptomatic individuals, for diagnosis of anogenital warts, or in the general population as part of panel testing

    Do not use HPV testing for routine STI panels

    PrEP-related STI screening

    PrEP-associated screening

    PrEP monitoring: Prior to beginning or while on HIV PrEP, the following STI screens meet criteria: qualitative NAAT screening for gonorrhea and chlamydia once every 3 months for MSM and once every 6 months for sexually active individuals; blood testing for syphilis once every 3 months for MSM and once every 6 months for sexually active individualsq3 or q6 months by risk

    Follow CDC PrEP screening guidance

    Not supported by evidence

    Tests explicitly not meeting criteria due to insufficient evidence

    Nucleic acid testing for resistance: Nucleic acid testing to determine antimicrobial susceptibility in N. gonorrhoeae or macrolide resistance in M. genitalium DOES NOT MEET CRITERIA

    Resistance NAATs not supported as standard clinical requirement

    Direct probe/quantitative NAAT not covered: Direct probe detection and/or quantitative NAAT for listed organisms (C. trachomatis, N. gonorrhoeae, HSV-1, HSV-2, T. pallidum, T. vaginalis) DOES NOT MEET CRITERIA

    Direct/quantitative NAATs not supported by evidence in this context

    Diagnostic testing recommendations

    Diagnostic testing and indications summarized from the clinical background and assay labeling:

    Chlamydia testing: NAAT is the gold standard for chlamydia diagnosis due to high sensitivity and specificity; recommended for symptomatic and asymptomatic screening in high-prevalence groups (e.g., young sexually active women, MSM).

    source: chunk 27

    Gonorrhea testing: NAAT is the preferred diagnostic test for gonorrhea; culture remains necessary for antimicrobial susceptibility testing when resistance is a concern.

    source: chunk 29

    Syphilis testing: Use two-tiered serologic testing algorithm comprising treponemal and nontreponemal tests; NAAT/PCR for T. pallidum is not FDA-approved and is not typically performed for genital syphilis.

    source: chunk 31

    HSV testing: For active lesions, PCR-based testing has the greatest sensitivity and specificity and is preferred along with viral culture; serology may be used in other contexts.

    source: chunk 32

    M. genitalium testing: M. genitalium is associated with urethritis and cervicitis; testing via NAAT is the diagnostic modality with clinical features including dysuria, discharge, and pelvic pain.

    source: chunk 28

    HPV testing and BD Onclarity indications: BD Onclarity HPV Assay (FDA-approved) identifies HPV 16, 18, 45 individually and detects other high-risk types; indicated for women meeting specific age and cytology criteria (e.g., women ≥21 with ASC-US, women ≥30 as adjunctive screening, women ≥25 as first-line primary screening).

    source: chunk 36 and 37

    PrEP associated screening: Before initiating or restarting PrEP, perform HIV Ag/Ab testing within one week, hepatitis B testing, and screening for chlamydia, gonorrhea, and syphilis; ongoing STI screening every 3–6 months while on PrEP.

    source: chunk 34

    Informational: Assay indications and evidence

    Assay-specific indicated uses and evidence summaries (informational):

    BD Onclarity HPV Assay indications: Indicated in women >=21 years with ASC-US to determine referral to colposcopy and to detect HR HPV genotypes 16, 18 and 45; in women >=30 years as adjunctive screening with cytology; in women >=25 years as first-line primary cervical cancer screening to detect high-risk HPV (including 16 and 18); positive 16/18 should prompt colposcopy.

    Manufacturer labeling; chunk 36-37 support

    Cepheid Xpert CT/NG intended use: FDA-approved NAAT for CT and NG using urogenital and extragenital specimens (pharynx, rectum); supports urine, patient-collected vaginal swabs, clinician-collected endocervical swabs, and pharyngeal and rectal swabs; provides rapid (~90 min) results.

    chunk 38

    Abbott Alinity m STI Assay use and performance: Multiplex RT-PCR assay detecting CT, TV, MG (RNA) and NG (DNA) from endocervical, clinician- or self-collected vaginal swabs and urine; first result <115 minutes; manufacturer reports high sensitivity and specificity in evaluations.

    chunk 39

    Analytical validity evidence summaries: Pooled and individual studies show high specificity (>97%) for NAATs on urine for CT and NG; near-patient NAAT sensitivity >98% and specificity ~99.4%; POCT antigen tests have substantially lower sensitivity than laboratory NAATs.

    chunks 40,46,47

    Syphilis testing insights: EIA-based syphilis screening tests show high sensitivity and specificity in some studies; molecular T. pallidum PCR has lower sensitivity than serology in many settings and may add limited value except for lesion testing or adjunctive use.

    chunks 41,44,45

    HSV testing insights: Serologic HSV-2 tests have high sensitivity but variable specificity leading to low positive predictive value in general populations; PCR and culture remain gold standards for lesion and CNS diagnostics.

    chunks 41,42,43

    Clinical utility of rapid CT/NG testing: Randomized trial in ED shows rapid GeneXpert testing for CT/NG reduced undertreatment to 0% and reduced overtreatment compared with standard care, supporting clinical utility of rapid NAATs for timely management.

    chunk 50

    Chlamydia and Gonorrhea Screening and Testing

    Covered when meeting guideline-based screening criteria and using recommended tests:

    Chlamydia/Gonorrhea screening criteria: Screen sexually active females aged ≤24 years; screen females ≥25 years who are at increased risk (new partner, multiple partners, partner with concurrent partners or an STI, inconsistent condom use, prior or coexisting STI, exchange sex, incarceration). For pregnant individuals follow pregnancy-specific screening timing.age and risk-based

    USPSTF Grade B for women

    Testing modality: Use NAATs for chlamydia and gonorrhea; test anatomic exposure sites (urogenital, rectal, pharyngeal) as indicated; consult NAAT product inserts for specimen types.NAAT preferred

    NAATs are more sensitive than culture; NAAT POC options available

    Gonorrhea culture indications: Maintain culture capacity for cases of suspected treatment failure, antimicrobial susceptibility monitoring, surveillance, and certain pediatric/extragenital cases; perform culture for urethral, cervical, ocular, pharyngeal, or rectal specimens as needed.clinical/surveillance indications

    CDC recommends culture capacity

    Syphilis Testing

    Covered when using recommended testing algorithms and clinical indications:

    Initial syphilis testing: Use both a nontreponemal test (e.g., VDRL or RPR) and a treponemal test (e.g., TP-PA, EIA, CIA) in combination to aid diagnosis; use darkfield microscopy or molecular tests for direct detection when available for early syphilis.dual testing

    Use of only one serologic test is insufficient

    Neurosyphilis evaluation: Patients with neurologic, ocular, or otologic symptoms should undergo CSF analysis including CSF-VDRL and CSF cell count/protein prior to treatment.symptoms present

    Follow-up evaluation per CDC guidance

    Pregnancy syphilis screening: Screen all pregnant individuals early in pregnancy; retest at 28 weeks and at delivery if at increased risk or per geography/personal risk factors.pregnancy timeline

    CDC recommends universal early screening

    HSV (Herpes Simplex Virus) Testing

    Covered when clinically indicated rather than for routine screening:

    Avoid routine serologic screening: Do not perform routine serologic screening for HSV-2 in asymptomatic adolescents and adults (including pregnant persons) due to high false-positive rates and psychosocial harms.not recommended for asymptomatic persons

    USPSTF recommends against routine serologic screening

    When to test: Type-specific HSV serologic assays are useful for recurrent or atypical genital symptoms with negative PCR/culture, clinical diagnosis without laboratory confirmation, or when a partner has genital herpes; consider in higher-risk patients (≥10 lifetime partners, HIV).symptomatic or partner status

    CDC guidance

    Mycoplasma genitalium Testing

    Covered in specific clinical scenarios:

    Indications: Test men with recurrent nongonococcal urethritis (NGU) and women with recurrent cervicitis using FDA-cleared NAAT when available; consider testing in PID. Resistance testing recommended if available to guide therapy.recurrent infection or PID

    CDC recommends resistance testing when available

    HPV Testing

    Covered per cervical cancer screening recommendations and limited clinical uses:

    Cervical screening: For persons aged 30-65 years: cytology every 3 years OR HPV test alone every 5 years OR cotest every 5 years; HPV tests are used for cervical cancer screening in women ≥30 only.age 30-65

    CDC guidance

    Not for male screening or general STI testing: Do not use HPV testing for male partners of women with HPV, for women <30 years, for diagnosis of genital warts, or as a general STI test.not recommended

    No approved test for HPV in men

    Trichomonas Testing and Follow-up

    Trichomonas testing and follow-up

    Diagnostic indications: Perform diagnostic testing for T. vaginalis for women seeking care for vaginal discharge; consider annual screening in high-prevalence settings and in asymptomatic women at high risk; use NAATs or FDA-cleared molecular assays over wet mount when possible.symptoms or high-risk settings

    CDC recommends NAATs for higher sensitivity

    Retesting after treatment: Retest sexually active women approximately 3 months after treatment due to high reinfection rates; if 3-month retest is not possible, retest at next healthcare visit within 12 months.~3 months

    CDC follow-up recommendation

    PrEP-related STI Screening

    Covered as part of PrEP monitoring:

    Baseline and interval testing: Prior to initiating PrEP, screen for HIV (Ag/Ab and RNA), syphilis, gonorrhea, chlamydia, and hepatitis B; repeat HIV testing at least every 3 months while on PrEP and assess for other STIs regularly (gonorrhea and syphilis at least every 3 months; chlamydia every 6 months for MSM/transgender women; heterosexually active people at least yearly).PrEP monitoring intervals

    CDC recommends STI screening frequency for PrEP users

    Guideline-based covered testing criteria (excerpt)

    Covered when testing matches guideline indications and specimen/site-specific recommendations:

    Chlamydia testing: NAAT is recommended (vaginal/cervical swab or first-void urine for females; first-void urine for males); obtain rectal or pharyngeal specimens when exposed; genotyping required for suspected LGV-positive specimens

    Indications include symptomatic urethritis, vaginal/cervical discharge with risk factors, PID, proctitis, neonatal pneumonia, and risk-based asymptomatic screening

    Gonorrhea testing: NAAT is the preferred test for detection; NAAT can be performed on urine and genital swabs; culture may be used when antimicrobial susceptibility testing is required

    Extragenital NAAT availability depends on local laboratory capacity

    Syphilis testing: Serology is usually used for syphilis diagnosis; algorithms include TT-based screening (EIA/ELISA/CLIA) or NTT-based screening (RPR/VDRL) or combined approaches; reflex quantitative NTT and confirmatory TTs per algorithmquantitative NTT titer ≥ 1:8 to 1:16 for reflex consideration as described

    Direct detection (PCR) is preferred for lesions or oral sites; darkfield no longer routine

    HSV testing: HSV DNA detection (NAAT/PCR) is the diagnostic gold standard for symptomatic herpes; type-specific serology may be useful in select groups (pregnant symptomatic, partners, recurrent/atypical disease)

    Serology not routine in asymptomatic patients

    M. genitalium testing: NAAT may be done on urine, cervical, vaginal, urethral or meatal swabs and endometrial biopsies

    Specific indications not detailed in excerpt

    Pregnancy screening: Pregnant people should be tested early in pregnancy for syphilis, HIV, hepatitis B, and hepatitis C; chlamydia and gonorrhea testing recommended for those at risk; rescreening in third trimester for certain groups (e.g., age <25 or increased chlamydia risk)

    Repeat testing may be needed per guideline

    Guideline-based coverage contexts

    Guideline-based testing recommendations and contexts from source societies:

    Prenatal syphilis testing: At a minimum, syphilis serology is recommended at the first prenatal visit; repeat testing at 28–32 weeks and at delivery in areas with outbreaks or ongoing risk or with ongoing maternal risk; newborns ideally should not be discharged until maternal syphilis results are known.timing: first visit; repeat at 28–32 weeks; at delivery in specified contexts

    CPS 2024 practice point supports repeat testing and newborn management

    Use of NAATs: NAATs are the preferred testing method for chlamydia, gonorrhea, LGV confirmation, and are preferred for HSV direct detection from lesions due to higher sensitivity and specificity.use NAAT when available

    BASHH, IUSTI and other guidelines recommend NAAT

    Syphilis serologic testing algorithm: Screen with an EIA/CLIA detecting IgM and IgG; confirm positive screening tests with a different treponemal test and perform a quantitative non-treponemal test (e.g., RPR); repeat negative serology at two weeks if chancres observed and microscopy/PCR negative.follow two-test approach and quantitative RPR when screening positive

    BASHH/UK National Guidelines 2024

    LGV testing indications: Test anyone with symptoms of LGV (hemorrhagic proctitis, primary lesions, suspected LGV-associated pharyngitis, secondary lesions, buboes, lymphadenitis); confirm C. trachomatis-positive specimens with an LGV-discriminatory NAAT.symptomatic indications trigger testing

    BASHH guidance

    Screening frequency for people on PrEP: Support people taking PrEP with regular HIV testing and STI screening every 3 months.every 3 months

    NICE guidance for people on PrEP

    Direct probe detection and/or quantitative NAAT for C. trachomatis, N. gonorrhoeae, HSV‑1, HSV‑2, T. pallidum, and T. vaginalis DO NOT MEET CRITERIA and are not covered under the situations described in this policy.

    NAAT/PCR for Treponema pallidum is not FDA‑approved for routine genital syphilis diagnosis and is not typically performed; the policy cites the lack of an internationally approved PCR for T. pallidum and emphasizes reliance on validated methods with appropriate quality controls.

    Point‑of‑care immunochromatographic antigen tests for C. trachomatis and N. gonorrhoeae have substantially lower sensitivity than laboratory NAATs (pooled POCT sensitivity ~37%–63% for chlamydia and 12.5%–70% for gonorrhea depending on sample), and therefore are not recommended as screening tests in this policy; near‑patient NAATs show much higher pooled sensitivity (>98%) and specificity (~99.4%).

    HPV testing is supported when used for cervical cancer screening or cancer‑related assessment per guideline‑based indications, but HPV NAAT is not recommended for general STI panel screening, for testing men, for routine screening of adolescents, or for diagnosis of anogenital warts because results would not alter management.

    Routine serologic screening for genital herpes (HSV‑2) in asymptomatic adolescents and adults, including pregnant persons, is not recommended due to high rates of false‑positive results and unclear benefit; type‑specific testing is reserved for specific clinical scenarios.

    HPV detection and typing is not recommended for diagnosis or management of anogenital warts because test results are not confirmatory and do not influence wart management decisions.

    Oncogenic HPV testing is not recommended for asymptomatic men or as part of general population STI testing; HPV NAATs are intended for cervical cancer screening in specified female age groups and are not appropriate as routine STI screening for men or for asymptomatic individuals outside guideline‑recommended cervical screening contexts.

    Procedure and proprietary test codes listed in this policy are provided as a general reference only; they may not be all‑inclusive and should be matched to the specific billed service and applicable coding guidance when submitting claims.

    The references and publication history section lists evidence sources and does not itself state coverage exclusions or medical necessity criteria; consult the body of the policy for coverage determinations supported by the cited literature and guideline documents.

    Multiple specific test types are explicitly identified as not meeting criteria in particular circumstances, including treponemal testing in individuals with prior syphilis, PCR/NAAT/antigen testing for syphilis, culture/antibody/antigen methods for chlamydia, rapid enzyme immunoassay for Trichomonas, NAAT screening for asymptomatic Mycoplasma genitalium, and direct probe/quantitative NAAT applications described in the policy.

    Use of NAAT or PCR for routine genital syphilis diagnosis is not supported by FDA approval or international standards per the policy; syphilis diagnosis is based primarily on two‑tiered serologic testing with treponemal and nontreponemal assays, with molecular methods reserved for specific adjunctive uses.

    Antigen POCTs for C. trachomatis demonstrate inadequate sensitivity for screening compared with laboratory or near‑patient NAATs and therefore are not recommended as screening tests; near‑patient NAATs offer substantially improved sensitivity but require equipment, electricity, and longer run times.

    Routine serologic screening for HSV in asymptomatic patients is not recommended; type‑specific serology may be useful only in defined clinical contexts such as recurrent or atypical symptoms, exposure to an infected partner, or specific counseling scenarios.

    Consistent with USPSTF and CDC guidance summarized in this policy, routine serological testing for HSV in asymptomatic individuals does not meet criteria and should not be performed as population screening.

    Routine HPV testing for men, adolescents, or women outside age‑based cervical cancer screening recommendations is not recommended; HPV tests are intended for cervical cancer screening in women per guideline age ranges and are not appropriate as a general STI screen.

    There are no 'not medically necessary' statements contained within the references and publication history section itself; those bibliographic entries support the coverage positions presented in the policy body.

    Procedure and Proprietary Test Codes

    Selected serology and culture CPT CodesCPT
    86592Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART)
    86593Syphilis test, non-treponemal antibody; quantitative
    86631Antibody; Chlamydia
    86632Antibody; Chlamydia, IGM
    86694Antibody; herpes simplex, non-specific type test
    86695Antibody; herpes simplex, type 1
    86696Antibody; herpes simplex, type 2
    86780Antibody; Treponema pallidum
    87081Culture, presumptive, pathogenic organisms, screening only
    87110Culture, Chlamydia, any source
    1–10 of 11
    1/2
    NAAT and HPV/other organism CPT CodesCPTCovered
    87624Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types, pooled
    87626Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only
    87660Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, direct probe technique
    87661Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique
    87797Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; direct probe technique, each organism
    87798Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism
    Narrative NAAT codes referencedmixed
    (unspecified codes referenced in text)Additional NAAT codes for Chlamydia trachomatis, Neisseria gonorrhoeae, Herpes simplex virus, Mycoplasma genitalium referenced in narrative
    Covered CPT/HCPCS and molecular assay Codes (partial list)CPTCovered
    87624Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types, pooled
    87626Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), separately reported high-risk types
    87660Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, direct
    87661Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique
    87797Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; direct probe technique, each organism
    87798Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism
    87799Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified
    87800Infectious agent detection by nucleic acid (DNA or RNA), quantification, each organism
    87808Infectious agent antigen detection by immunoassay with direct optical observation; Trichomonas vaginalis
    PLA/Proprietary test Codes listedCPTCovered
    0210USyphilis test, non-treponemal antibody, immunoassay, quantitative (RPR) - Proprietary test: BioPlex 2200 RPR Assay - Quantitative
    0483UInfectious disease (Neisseria gonorrhoeae), sensitivity, ciprofloxacin resistance (gyrA S91F point mutation)
    0484UInfectious disease (Mycoplasma genitalium), macrolide sensitivity (23S rRNA point mutation)
    Proprietary multiplex assay descriptionsmixed
    UnspecifiedMultiple organism multiplex assays (eg, Abbott Alinity m STI Assay) described with specimen types and reporting per pathogen; specific CPT usage referenced in text.
    NTT dilution — quantitative reflex threshold
    Reflex quantitative NTT dilution rangeReflex quantitative non-treponemal test (RPR or VDRL) should reach at least a 1:8 to 1:16 dilution
    PurposeQuantitative NTT titers are used for baseline measurement and to monitor treatment response (test-of-cure)
    Preferred assaysRPR or VDRL performed quantitatively when using NTT as part of syphilis algorithm
    Reflex workflow notePerform reflex quantitative NTT and follow confirmatory treponemal testing per syphilis algorithm when screening tests are positive

    Provider Responsibilities, Prior Authorization & Documentation

    Prior Authorization

    Meet authorization & medical necessity

    Services must meet authorization and medical necessity guidelines for the procedure, diagnosis, and the member’s state of residence; coverage does not guarantee reimbursement.

    Prior Authorization

    Prior authorization not specified — follow manufacturer labeling

    No explicit prior authorization requirements are stated in the policy excerpt; follow manufacturer indications (e.g., BD Onclarity) and standard laboratory regulations when ordering assays.

    Prior Authorization

    No PA requirements listed in excerpt

    This policy excerpt does not list specific prior authorization requirements or identify affected billing codes for STI diagnostic tests.

    Note

    Order tests per labeling and guideline indications

    Providers must follow the explicit clinical and laboratory guidance in the policy when ordering tests; use manufacturer labeling and guideline-based indications to justify testing.

    Prior Authorization

    No PA for routine STI tests in excerpt

    No prior authorization requirement for STI diagnostic tests is specified in these sections of the policy.

    Billing Rule

    Reference applicable procedure codes when billing

    Procedure codes for syphilis, chlamydia, gonorrhea, HSV, HPV, Trichomonas, Mycoplasma genitalium and other STI tests are listed in the policy and should be referenced when submitting claims.

    Billing Rule

    Use listed procedure & proprietary test codes for claims

    Proprietary and procedure codes (CPT/HCPCS and PLA codes) are provided for reference in the policy; use the appropriate code per payer rules and match specimen source to billed code.

    • Match specimen type (vaginal, endocervical, rectal swab, urine) to the code and claim.
    • Use proprietary PLA codes (e.g., 0210U, 0483U, 0484U) as applicable for proprietary assays.
    Prior Authorization

    No prior authorization requirements in this section

    This section of the policy does not specify any prior authorization requirements for the listed STI diagnostic services.

    Documentation Required

    Submit accurate coding and documentation

    Providers should ensure submitted claims include accurate coding and supporting documentation per industry-standard coding guidelines; failure may result in denial or recoupment.

    • Code claims according to CPT, HCPCS, ICD-10 and other standard coding guidance.
    • Submit documentation supporting medical necessity and the procedure performed.
    Step Therapy

    Use two-tiered serologic testing for syphilis

    For syphilis diagnosis, use a two-tiered serologic testing algorithm combining treponemal and nontreponemal tests; relying on a single serologic test is insufficient for diagnosis.

    • Perform both a treponemal test (e.g., TP-PA, EIA/CLIA) and a nontreponemal test (e.g., RPR or VDRL) per standard algorithms.
    • Recognize NAAT/PCR for T. pallidum is not FDA-approved for routine genital syphilis diagnosis.
    Note
    Note
    Note
    Note
    Note
    Step Therapy

    No step therapy requirements stated

    No step therapy requirements are described in this policy section.

    Note
    Documentation Required

    Document age, cytology, screening history for BD Onclarity

    Providers must document patient age, cervical cytology results (e.g., ASC-US), screening history, and risk factors when ordering BD Onclarity HPV testing to support appropriate use per manufacturer indications.

    Note
    Documentation Required

    Document prenatal STI testing and repeat tests as indicated

    Pregnancy screening must include documentation of syphilis, HIV, hepatitis B and C testing early in pregnancy; repeat testing may be required at 28–32 weeks and at delivery for individuals at increased risk.

    • Document timing and results of maternal syphilis testing to support newborn management.
    • Rescreen pregnant individuals per risk (e.g., age <25, new partner, ongoing risk).
    Documentation Required

    Perform quantitative RPR/VDRL for syphilis reflex testing

    When serologic testing for syphilis is used, perform quantitative non-treponemal testing (RPR or VDRL) quantitatively to allow reflex/interpretation and follow reflex confirmatory testing per algorithm.

    • Quantitative NTT titers (RPR/VDRL) should be reported to permit reflex testing and interpretation.
    • Reflex to confirmatory treponemal tests as described by testing algorithm.
    Note
    Documentation Required

    Use correct specimen type per assay labeling

    Use the appropriate specimen type and follow assay labeling when ordering proprietary or multiplex assays; the policy lists specimen types matched to each assay.

    • Match billed procedure codes to the specimen source (vaginal, endocervical, rectal swab, female or male urine).
    • Follow manufacturer specimen instructions for proprietary assays (e.g., Abbott Alinity, Cepheid).
    Note
    Denial Risk

    Claims may be denied or recouped for improper coding/documentation

    Failure to follow coding/billing guidelines, reimbursement policies, or to submit required documentation may result in claim denial or recoupment.

    Denial Risk

    Do not use assays outside manufacturer indications

    Using assays outside FDA or manufacturer indications (for example BD Onclarity outside indicated age or cytology contexts) may lead to unsupported testing decisions and denials.

    Note
    Denial Risk

    Avoid single-test syphilis diagnoses — use combined tests

    Using only one type of serologic test (nontreponemal or treponemal) is insufficient for syphilis diagnosis and can produce false-negative or false-positive conclusions; perform combined testing as required.

    Note
    Note
    Billing Rule

    Verify procedure codes — policy list is for reference only

    Procedure codes shown in Medical Policy documents are provided as a general reference and may not be all-inclusive; verify codes and payer rules before billing.

    Note

    Clinical Background and Rationale

    Sexually transmitted infections include bacterial and viral pathogens transmitted through sexual contact and can result in significant sequelae such as pelvic inflammatory disease, infertility, neurologic or cardiac complications, and cancers. This policy focuses coverage and limitations for testing of select common STIs (C. trachomatis, N. gonorrhoeae, T. pallidum, T. vaginalis, HSV, HPV, and guidance for M. genitalium) and aligns testing recommendations with guideline‑based indications.

    Definitions and Key Terms

    Covered pathogens
    Covered pathogens (policy scope)Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum, Trichomonas vaginalis, Herpes simplex virus (HSV), Human papillomavirus (HPV), Mycoplasma genitalium
    Exclusions / related policiesOther infections (HIV, Hepatitis B/C) are addressed in separate policies (AHS-M2116, AHS-G2036)
    Clinical focusPolicy defines coverage/limits for diagnostic testing of the listed pathogens across screening and symptomatic indications
    NAAT — definition and general notes
    DefinitionNucleic acid amplification testing (NAAT): laboratory methods (eg, PCR, RT-PCR, TMA) that detect pathogen nucleic acid (DNA or RNA)
    RoleNAATs are the preferred/most sensitive tests for detecting C. trachomatis and N. gonorrhoeae and are recommended for many STI diagnoses and some HPV assays
    Specimen/site applicabilityNAATs are used on urogenital and, when validated, extragenital sites (rectal, pharyngeal) — check product inserts for permitted specimen types
    BD Onclarity HPV Assay
    Test descriptionBD Onclarity HPV Assay: FDA-approved qualitative PCR-based (NAAT) assay performed on cervical swabs
    Genotyping capabilityIdentifies HPV types 16, 18, and 45 individually and concurrently detects other high-risk HPV types (eg, 31, 51, 52, 33/58, 35/39/68, 56/59/66)
    Indications per manufacturerIndicated for women ≥21 with ASC-US as triage, women ≥30 adjunctive screening with cytology, and women ≥25 as a first-line primary screening option; positive 16/18 prompts colposcopy
    NAAT — assay types and cross-platform notes
    NAAT across platformsNAAT encompasses PCR-based, RT-PCR, TMA and other nucleic acid amplification methods used across multiple FDA-cleared platforms (eg, Cepheid Xpert, Abbott Alinity) for STI detection
    Performance and throughput examplesNear-patient NAAT (Cepheid Xpert) provides rapid results (~90 minutes); multiplex assays (Abbott Alinity m) detect multiple targets with first result <115 minutes
    Use casesNAATs are preferred for CT/NG, LGV confirmation, and HSV lesion testing due to higher sensitivity and specificity
    ASC-US — definition and relevance
    ASC-US definitionAtypical squamous cells of undetermined significance (ASC-US) — a cervical cytology result used to triage for HPV testing (eg, BD Onclarity) to determine need for colposcopy
    Clinical relevanceHPV testing for ASC-US is indicated in women ≥21 per manufacturer labeling and guidelines to guide management
    DocumentationWhen ordering HPV tests for ASC-US triage, document cytology result and relevant screening history per manufacturer guidance
    Nontreponemal test (NTT)
    DefinitionNontreponemal test (NTT): serologic assays that detect lipoidal antibodies (eg, RPR, VDRL)
    Clinical useUsed in combination with treponemal tests for syphilis diagnosis and for quantitative titers to monitor treatment response (test-of-cure)
    Reflex testingPerform quantitative NTT reflex (eg, RPR/VDRL) per algorithm; recommended reflex dilution thresholds described in policy
    Treponemal test (TT)
    DefinitionTreponemal test (TT): serologic assays that detect antibodies specific to Treponema pallidum (eg, TP-PA, EIA, CIA)
    BehaviorTreponemal tests often remain reactive for life despite treatment and are used with NTTs in diagnostic algorithms
    Role in two-step testingPositive screening treponemal tests should be confirmed with a different treponemal test and a quantitative NTT per recommended algorithms
    NAAT — preferred method for CT/NG
    Preferred method for CT/NGNAAT is the preferred and most sensitive method for detecting Chlamydia trachomatis and Neisseria gonorrhoeae
    Specimen considerationsNAATs can be performed on urine and genital swabs; test extragenital sites (rectal, pharyngeal) when exposure indicates and laboratory validation permits
    Culture roleCulture is less sensitive than NAAT but is necessary when antimicrobial susceptibility testing for N. gonorrhoeae is required
    TT and NTT — abbreviations and roles
    AbbreviationsTT = Treponemal Test (eg, TPHA, TPPA, EIA/ELISA/CLIA); NTT = Nontreponemal Test (eg, RPR or VDRL)
    RolesTTs detect specific anti-T. pallidum antibodies (often lifelong); NTTs detect lipoidal antibodies and are used quantitatively for monitoring and staging
    Algorithm noteUse TT and NTT in combination per two-step syphilis testing recommendations; use reflex quantitative NTT when indicated
    HSV DNA detection
    DefinitionHSV DNA detection: nucleic acid-based testing (eg, PCR/NAAT) to detect herpes simplex virus DNA from lesion specimens
    Gold standard statementHSV DNA detection by PCR/NAAT is considered the diagnostic gold standard for symptomatic genital herpes (direct lesion testing)
    Serology caveatType-specific serology may be useful in select clinical scenarios (recurrent/atypical symptoms, partner with genital herpes) but is not recommended for routine asymptomatic screening
    NAAT — primary testing recommendation
    Recommendation summaryNAAT is the recommended primary testing method for chlamydia, gonorrhea, LGV confirmation, and preferred for HSV lesion testing due to superior sensitivity and specificity
    Platform examplesFDA-cleared NAAT platforms referenced include Cepheid Xpert CT/NG and Abbott Alinity m STI assay; check product inserts for specimen types and indications
    Clinical implicationOrder NAATs for symptomatic infections and guideline-based screening; obtain site-specific specimens when exposure warrants
    Two-step syphilis testing
    DefinitionTwo-step syphilis testing: use of treponemal EIA/CLIA screening (IgM/IgG) followed by a different treponemal confirmatory test and a quantitative non-treponemal test (eg, RPR) when screening is positive
    Workflow noteAlgorithms may start with TT-based or NTT-based screening; positive results should trigger confirmatory testing and reflex quantitative NTT per guidance
    Use casesTwo-step testing supports diagnosis in asymptomatic screening, symptomatic disease, and prenatal screening contexts
    NAAT and probe techniques
    DefinitionNAAT and probe techniques encompass direct probe, amplified probe, multiplex, and quantification methods for detecting pathogen nucleic acid (DNA/RNA)
    Coding linkageMultiple CPT/HCPCS codes reference specific NAAT and probe techniques for CT, NG, TV, HPV, MG, HSV and multiplex assays (eg, 87624, 87626, 87660, 87661, 87797, 87798)
    Specimen linkageTechnique selection and coding depend on organism(s) detected and specimen type (urine, cervical/vaginal swab, rectal, pharyngeal)
    Proprietary tests — examples and specimen ties
    Proprietary assays namedExamples include Abbott Alinity m STI Assay, BioPlex 2200 Syphilis Total & RPR Assay, Cepheid Xpert CT/NG, BD Onclarity HPV Assay
    Specimen tiesProprietary assays list permitted specimen types (eg, endocervical/vaginal swabs, ThinPrep PreservCyt, male/female urine, rectal/pharyngeal swabs) in manufacturer labeling
    Coding/PLA examplesProprietary tests are linked to PLA/CPT codes (eg, 0210U for BioPlex quantitative RPR; 0483U/0484U for resistance assays) and may require specific coding
    CDC guidance and laboratory recommendations
    CDC guidance referencedPolicy references CDC clinical guidance and laboratory recommendations for syphilis, chlamydia, gonorrhea, HSV, and other STIs (eg, CDC Laboratory Recommendations for Syphilis Testing 2024)
    Role in algorithmsCDC guidance supports two-test syphilis algorithms, use of NAATs for CT/NG, and laboratory approaches for lesion-based testing
    Implementation noteFollow CDC recommendations for specimen selection, testing frequency (eg, prenatal syphilis screening timing), and culture when susceptibility testing is needed
    USPSTF recommendations
    USPSTF topics citedUSPSTF screening recommendations for chlamydia, gonorrhea, and syphilis are cited to support screening stances
    Screening grade summaryUSPSTF gives Grade B recommendations for chlamydia and gonorrhea screening in sexually active females ≤24 and higher-risk women ≥25
    Policy useUSPSTF recommendations are used to define guideline-based screening indications incorporated into coverage criteria

    Policy Revision History

    2026-06-16governance_approvalLatest

    Original documentation and governance approval of the policy.